Clinical Practice

Use the tool below to view all available Medtelligence Series

Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
CME/CE
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
0.25 credits
- Sayna Norouzi, MD
0.25 credits
Crossing Home Plate – Building a Winning Team Culture
Crossing Home Plate – Building a Winning Team Culture
MinuteCE®
Crossing Home Plate – Building a Winning Team Culture
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Turning the Double Play – Comprehensive Secondary Prevention
Turning the Double Play – Comprehensive Secondary Prevention
MinuteCE®
Turning the Double Play – Comprehensive Secondary Prevention
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
MinuteCE®
ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 credits 6 episodes
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 credits 6 episodes
Swing for the Fences – LDL-C as the Power Hitter
Swing for the Fences – LDL-C as the Power Hitter
MinuteCE®
Swing for the Fences – LDL-C as the Power Hitter
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CE
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD; Julio Núñez, MD, PhD
0.25 credits
- Patrick Rossignol, MD, PhD
- Julio Núñez, MD, PhD
0.25 credits
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Nephrology
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
- Brendon Neuen, MBBS, PhD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD; Gil Yosipovitch, MD
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD; Ahmad Masri, MD, MS
1.00 program credit
- Anjali Owens, MD
- Ahmad Masri, MD, MS
1.00 program credit
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS; Anjali Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Cardiology
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
- Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Cardiology
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
- Roxana Mehran, MD, FSCAI

Clinical Practice

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

Clinical Practice

Popular

Title

NEED HELP?

Contact us